| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 51,66 | 51,86 | 13:03 | |
| 51,52 | 51,88 | 13.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 52,00 | 19 | |||
| 51,88 | 18 | |||
| 51,86 | 18 | |||
| 51,84 | 27 | |||
| 51,80 | 165 | |||
| 51,78 | 165 | |||
| 51,75 | 165 | |||
| 51,72 | 165 | |||
| 51,69 | 165 | |||
| 51,68 | 156 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/brm.htm [/URL] | ||||
| 165 | 51,51 | |||
| 165 | 51,49 | |||
| 156 | 51,47 | |||
| 27 | 51,36 | |||
| 18 | 51,34 | |||
| 18 | 51,32 | |||
| 20 | 50,000 | |||
| 110 | 36,600 | |||
| 1.077 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.756 | 0,605 | 1.063 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 13.03.2026 | 14:31:41 | 51,93 | 1 |
| 13.03.2026 | 14:30:06 | 51,76 | 28 |
| 13.03.2026 | 14:30:01 | 51,70 | 157 |
| 13.03.2026 | 14:30:01 | 51,70 | 60 |
| 13.03.2026 | 14:30:01 | 51,70 | 80 |
| 13.03.2026 | 14:30:01 | 51,70 | 165 |
| 13.03.2026 | 14:30:01 | 51,70 | 38 |
| 13.03.2026 | 12:21:05 | 51,37 | 15 |
| 13.03.2026 | 09:55:44 | 51,50 | 25 |
| 13.03.2026 | 09:04:36 | 51,15 | 98 |
| 13.03.2026 | 09:04:36 | 51,14 | 1 |
| 13.03.2026 | 09:04:36 | 51,14 | 7 |
| Tagesumsatz Xetra | +0,44 +0,86 % | 687 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | 1.800 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB Aktie jetzt für 0€ handeln | |||||
| Do | Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board | 13 | Investing.com | ||
| Do | Is Bristol Myers' Deep Pipeline the Key to Future Growth? | 23 | Zacks | ||
| Do | Bristol Myers Squibb's Sotyktu approved by US FDA for psoriatic arthritis | 4 | PMLiVE | ||
| Di | UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms | 20 | Insider Monkey |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Fr | EQT exits Galderma Group AG in full via largest sponsor-backed block trade ever | PR Newswire | EQT completes final sell-down in Galderma, a global dermatology company delivering science-backed solutions to healthcare professionals, consumers and patients worldwideUnder EQT's ownership... ► Artikel lesen | |
| Do | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | GlobeNewswire (Europe) | TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA... ► Artikel lesen | |
| Do | TerrAscend Reports Fourth Quarter and Full Year 2025 Financial Results | GlobeNewswire (Europe) | Net Revenue of $66.1 million for Q4 2025 and $260.6 Million for FY 2025 Gross Profit Margin of 52.1% for Q4 2025 and 52.3% for FY 2025 from continuing operations Q4 2025 Net Cash provided from continuing... ► Artikel lesen | |
| Fr | Im Windschatten von Novo Nordisk: Dänisches Pharma-IPO voraus? | Der Aktionär | Dänemark und Pharma? In diesem Zusammenhang führt kein Weg an Novo Nordisk vorbei. Das Unternehmen, dessen Wurzeln bis ins Jahr 1923 reichen, war einst das wertvollste börsennotierte Unternehmen Europas.... ► Artikel lesen | |
| Fr | Novartis Pharma AG: Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa | GlobeNewswire (Europe) | Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis... ► Artikel lesen |